


1. Drug-A is mainly metabolized by the liver and is a substrate of CYP2C19. The pharmacokinetic properties of drug-A are described below:  
F (oral) = 24%  
 $f_u = 13\%$   
elimination half-life  $t_{1/2} = 3.9$  hours  
 $V_d = 4.3$  L/kg
  - a. Based on suitable equations, what would be the change in hepatic clearance of drug-A in patients who are CYP2C19 poor metabolizers when it is given by oral administration. **(10 points)**
  - b. Based on suitable equations, explain how a change in (1) hepatic blood flow or (2) plasma protein binding would affect hepatic clearance of drug-A when it is given by intravenous administration. **(10 points)**
2. For bioequivalence studies, why are  $C_{max}$  and AUC acceptable to evaluate that two drug products are bioequivalent. **(10 points)**.
3. A drug has the following pharmacokinetic properties:  
 $f_u = 0.2$   
 $f_e = 0.6$   
elimination half-life  $t_{1/2} = 0.231$  hours  
This drug was given to a male patient (80 kg) by intravenous infusion at a rate of 240 mg/hr. At 7 hours after infusion, the plasma drug concentration was 10  $\mu\text{g/ml}$ .
  - (a) What is the apparent volume of distribution for this drug? **(5 points)**
  - (b) What is the probable mechanism for renal clearance of this drug? **(10 points)**
4. Describe the applications of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System). **(10 points)**
5. P-glycoprotein (MDR1; ABCB1) is an efflux transporter expressed at the intestine, liver, kidney, brain, and many others. Describe the roles of P-glycoprotein in ADME of its substrates. **(20 points)**

見背面

6. Describe and explain the pharmacokinetic properties for drugs that are sensitive to be considered for a bridging study. **(20 points)**
7. The followings describe the relationship among three pharmacodynamic parameters and the number of *Klebsiella pneumoniae* (indicated by CFU) in the lungs of neutroponic mice after 24-hr therapy with cefotaxime. Describe how these findings are related to the PK/PD properties of cefotaxime. **(5 points)**



Relationship between three pharmacodynamic parameters and the number of *Klebsiella pneumoniae* in the lungs of neutroponic mice after 24-hr therapy with cefotaxime. Each point represents one mouse.

試題隨卷繳回